UK – Novo Nordisk’s Saxenda bags NICE recommendation

Novo Nordisk’s obesity management treatment Saxenda (liraglutide) has been recommended for use by the UK’s National Institute for Health and Care Excellence (NICE).

Saxenda will be offered to adults with non-diabetic hyperglycaemia who have a body mass index (BMI) of at least 35kg per m2 and have a high risk of cardiovascular disease due to risk factors including high blood pressure or high cholesterol levels.

According to NICE, the pre-filled injection pens will be prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service.

Individuals who have been referred to a tier 3 service have usually been offered weight management interventions in a local, intensive lifestyle change programme first…